Article

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instability

2026-06-21

Abstract excerpt

Osimertinib is the current standard-of-care for treatment-naive patients with EGFR mutation-positive advanced/metastatic non-small cell lung cancer (NSCLC), however resistance inevitably emerges. Osimertinib does not eradicate all cancer cells even in culture, leaving a long-lasting sub-population of Drug Tolerant Persister (DTP) cells that is common to many chemotherapeutics. The DTP population is non-proliferati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c8ba2153-96d8-50d4-b125-360721ab59c6
DOI: 10.64898/2026.06.19.733326

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instabilityDOI 10.64898/2026.06.19.733326Read

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic ResistanceSemantic proximity Read

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read

Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapiesSemantic proximity Read

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Semantic proximity Read

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in <i>EGFR</i> -mutant NSCLCSemantic proximity Read

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read

Cancer drug-tolerant persister cells: from biological questions to clinical opportunitiesSemantic proximity Read

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.Semantic proximity Read